Atossa Therapeutics, Inc.
NASDAQ Capital MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Steven C. Quay
- Full Time Employees
- 16
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 448 NW Market Street Seattle WA United States of America 98104
- IPO Date
- Nov 8, 2012
- CIK
- 0001488039
- Website
- atossatherapeutics.com
- Similar Companies
- Business
- Atossa Therapeutics, Inc. (Nasdaq: ATOS) is a clinical-stage biopharmaceutical company focused on developing innovative oral therapies for the treatment of breast cancer and other breast conditions. The company offers a pipeline of proprietary product candidates, including (endoxifen), a selective estrogen receptor modulator indicated for the prevention of breast cancer in high-risk women and potential treatment of breast cancer tissue; (vacuolar ATPase inhibitor), a topical formulation designed to address benign breast disease symptoms such as cyclic mastalgia and breast density; and (AREase inhibitor), an investigational drug targeting abnormal cell proliferation in the breast. Atossa operates primarily in the United States, with its corporate headquarters in Seattle, Washington, and was originally founded in 2009. The company's target markets include patients at high risk for breast cancer, those with precancerous breast conditions, and individuals seeking non-invasive breast health solutions within the oncology and women's health segments. In late 2024, Atossa announced positive topline results from its Phase 2 KARISMA-Endoxifen study, demonstrating significant reductions in mammographic breast density with oral endoxifen, positioning it as a potential first-in-class therapy for breast cancer prevention. The company expanded its clinical efforts in 2025 with the initiation of the Phase 2b EndeavorRx study evaluating (vacuolar ATPase inhibitor) gel for reducing breast density and associated cancer risk. Additionally, Atossa strengthened its strategic position through a collaboration with a leading contract research organization for ongoing trials and reported successful completion of a $5 million registered direct offering to support pipeline advancement. These developments underscore Atossa's shift toward late-stage clinical validation and commercialization readiness in the breast cancer prevention market.
Atossa Therapeutics Announces Presentation of Mechanism-Driven (Z)-Endoxifen Data in McCune-Albright Syndrome at AACR Special Conference on Rare Cancers
Atossa Therapeutics Announces Closing of Registered Direct Offering of up to $16.5 Million in Gross Proceeds
Atossa Therapeutics Announces Registered Direct Offering of up to $16.5 Million in Gross Proceeds
Atossa Therapeutics Announces ASCO 2026 Abstracts Highlighting (Z)-Endoxifen Activity Across ESR1 Mutations and Ongoing EVANGELINE Phase 2 Trial
Atossa Therapeutics Announces Acceptance of Manuscript Highlighting Utrophin-Modulation Potential of (Z)-Endoxifen in Duchenne Muscular Dystrophy
Atossa Therapeutics, Inc. (ATOS) Discusses Challenges in Breast Cancer Drug Development and Innovation in Clinical Research Transcript
Atossa Therapeutics to Host Virtual KOL Event Featuring Dr. Laura Esserman to Discuss Development of (Z)-Endoxifen in ER-Positive Breast Cancer
Atossa Therapeutics Reports First Quarter 2026 Financial Results and Provides a Corporate Update
Atossa Therapeutics Announces Publication of KARISMA Endoxifen Trial Demonstrating Significant Reduction in Mammographic Breast Density in Healthy Premenopausal Women
Atossa Therapeutics Receives FDA Rare Pediatric Disease Designation for (Z)-Endoxifen for McCune-Albright Syndrome
Atossa Therapeutics Reports Fourth Quarter and Year-End 2025 Financial Results and Provides a Corporate Update
Hyperfine (NASDAQ:HYPR) and Atossa Genetics (NASDAQ:ATOS) Critical Comparison
The Patent Cliff is Coming, Driving Smart Money Towards Precision Oncology
Atossa Therapeutics Strengthens Clinical Leadership Team with the Addition of Two Experienced Biopharma Executives
Atossa Therapeutics Presents Clinical Trial Update Highlighting (Z)-Endoxifen Research at the 2026 MDA Clinical & Scientific Conference
Atossa Genetics Inc. (NASDAQ:ATOS) Receives $95.00 Consensus PT from Analysts
Atossa Genetics Inc. (NASDAQ:ATOS) Short Interest Up 29.7% in January
Atossa Therapeutics Issues Letter to Shareholders Highlighting 2025 Accomplishments and 2026 Outlook
Atossa Therapeutics Maintains Strong Market Position for (Z)-Endoxifen for Duchenne Muscular Dystrophy as Congress Reauthorizes Priority Review Voucher Program
Atossa Genetics (NASDAQ:ATOS) Shares Set to Reverse Split on Monday, February 2nd